Zacks Research Expects Lower Earnings for Oncolytics Biotech

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Analysts at Zacks Research dropped their FY2026 earnings estimates for Oncolytics Biotech in a report issued on Thursday, August 27th. Zacks Research analyst D. Bautz now expects that the company will post earnings of ($0.27) per share for the year, down from their previous forecast of ($0.24). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.27) per share.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03).

ONCY has been the topic of a number of other reports. HC Wainwright cut their price objective on shares of Oncolytics Biotech to $5.00 and set a “buy” rating on the stock in a report on Wednesday, August 19th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings upgraded shares of Oncolytics Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Oncolytics Biotech presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Oncolytics Biotech Trading Up 0.2%

NASDAQ ONCY opened at $0.84 on Wednesday. The business has a fifty day simple moving average of $0.85 and a 200 day simple moving average of $0.91. Oncolytics Biotech has a 12 month low of $0.73 and a 12 month high of $1.51. The firm has a market capitalization of $107.11 million, a P/E ratio of -2.47 and a beta of 1.13.

Hedge Funds Weigh In On Oncolytics Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Scientech Research LLC purchased a new position in shares of Oncolytics Biotech in the third quarter worth about $25,000. Vantage Point Financial LLC bought a new position in Oncolytics Biotech in the 2nd quarter worth approximately $28,000. Blair William & Co. IL purchased a new position in Oncolytics Biotech in the 4th quarter valued at approximately $28,000. Security National Bank of Sioux City Iowa IA bought a new stake in Oncolytics Biotech during the 4th quarter valued at $29,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of Oncolytics Biotech during the fourth quarter worth $30,000. Institutional investors own 6.82% of the company’s stock.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.